Abstract
QUESTION: A 23-year-old patient of mine has been taking St John's wort for postpartum depression for about 2 years. She is now planning her second pregnancy. Is she or her fetus at risk if she continues to take the herbal therapy? ANSWER: Despite the widespread availability and use of St John's wort and extensive research on the herb, there are almost no data on reproductive safety. At this stage, therefore, St John's wort cannot be recommended as safe therapy during pregnancy.
Full Text
The Full Text of this article is available as a PDF (96.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Einarson A., Lawrimore T., Brand P., Gallo M., Rotatone C., Koren G. Attitudes and practices of physicians and naturopaths toward herbal products, including use during pregnancy and lactation. Can J Clin Pharmacol. 2000 Spring;7(1):45–49. [PubMed] [Google Scholar]
- Ernst Edzard. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann Intern Med. 2002 Jan 1;136(1):42–53. doi: 10.7326/0003-4819-136-1-200201010-00010. [DOI] [PubMed] [Google Scholar]
- Grush L. R., Nierenberg A., Keefe B., Cohen L. S. St John's wort during pregnancy. JAMA. 1998 Nov 11;280(18):1566–1566. doi: 10.1001/jama.280.18.1566. [DOI] [PubMed] [Google Scholar]
- Hypericum Depression Trial Study Group Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002 Apr 10;287(14):1807–1814. doi: 10.1001/jama.287.14.1807. [DOI] [PubMed] [Google Scholar]
- Linde K., Mulrow C. D. St John's wort for depression. Cochrane Database Syst Rev. 2000;(2):CD000448–CD000448. doi: 10.1002/14651858.CD000448. [DOI] [PubMed] [Google Scholar]
- Müller W. E., Kasper S. Clinically used antidepressant drugs. Pharmacopsychiatry. 1997 Sep;30 (Suppl 2):71–71. doi: 10.1055/s-2007-979521. [DOI] [PubMed] [Google Scholar]
- Müller W. E., Singer A., Wonnemann M., Hafner U., Rolli M., Schäfer C. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry. 1998 Jun;31 (Suppl 1):16–21. doi: 10.1055/s-2007-979341. [DOI] [PubMed] [Google Scholar]
- Nathan P. The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.). Mol Psychiatry. 1999 Jul;4(4):333–338. doi: 10.1038/sj.mp.4000557. [DOI] [PubMed] [Google Scholar]
- Rayburn W. F., Christensen H. D., Gonzalez C. L. Effect of antenatal exposure to Saint John's wort (Hypericum) on neurobehavior of developing mice. Am J Obstet Gynecol. 2000 Nov;183(5):1225–1231. doi: 10.1067/mob.2000.108889. [DOI] [PubMed] [Google Scholar]
- Rayburn W. F., Gonzalez C. L., Christensen H. D., Stewart J. D. Effect of prenatally administered hypericum (St John's wort) on growth and physical maturation of mouse offspring. Am J Obstet Gynecol. 2001 Jan;184(2):191–195. doi: 10.1067/mob.2001.108339. [DOI] [PubMed] [Google Scholar]
- Woelk H., Burkard G., Grünwald J. Benefits and risks of the hypericum extract LI 160: drug monitoring study with 3250 patients. J Geriatr Psychiatry Neurol. 1994 Oct;7 (Suppl 1):S34–S38. doi: 10.1177/089198879400700110. [DOI] [PubMed] [Google Scholar]